Compare MRDN & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRDN | NNNN |
|---|---|---|
| Founded | N/A | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.3M | 154.1M |
| IPO Year | 2008 | 2023 |
| Metric | MRDN | NNNN |
|---|---|---|
| Price | $8.79 | $3.87 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $19.73 | N/A |
| AVG Volume (30 Days) | 33.5K | ★ 46.3K |
| Earning Date | 11-10-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $182,863,373.00 | N/A |
| Revenue This Year | $12.08 | N/A |
| Revenue Next Year | $10.93 | N/A |
| P/E Ratio | ★ $28.74 | $446.57 |
| Revenue Growth | ★ 21.01 | N/A |
| 52 Week Low | $6.01 | $3.09 |
| 52 Week High | $16.09 | $44.73 |
| Indicator | MRDN | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 30.02 | 45.94 |
| Support Level | N/A | $3.21 |
| Resistance Level | $14.87 | $6.95 |
| Average True Range (ATR) | 0.69 | 0.40 |
| MACD | -0.03 | 0.14 |
| Stochastic Oscillator | 8.42 | 74.73 |
Meridian Holdings Inc is engaged in the online gaming and betting business, providing sports betting, online casino, and gaming operations across multiple jurisdictions in Europe, Africa, and Central and South America. The company has three reportable segments: MeridianBet Group, GMAG, and RKings & CFAC. The MeridianBet Group segment includes retail and online sports betting, casinos, and related gaming operations. The GMAG segment focuses on the resale of third-party gaming content, mainly serving customers in the Asia-Pacific region. The RKings & CFAC segment is involved in pay-to-enter prize competitions and trade promotions conducted in the United Kingdom and Australia. It generates the majority of its revenue from the MeridianBet Group segment.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).